BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23142206)

  • 1. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm?
    Roch AM; Barron MR; Tann M; Sandrasegar K; Hannaford KN; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2015 Jul; 221(1):48-56. PubMed ID: 26095551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Nagai K; Doi R; Ito T; Kida A; Koizumi M; Masui T; Kawaguchi Y; Ogawa K; Uemoto S
    J Hepatobiliary Pancreat Surg; 2009; 16(3):353-8. PubMed ID: 19280108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
    Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
    Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography's standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.
    Suto H; Ando Y; Matsukawa H; Oshima M; Kamada H; Kobara H; Masaki T; Tanaka K; Norikane T; Nishiyama Y; Hirao T; Kumamoto K; Okano K
    HPB (Oxford); 2024 Feb; 26(2):291-298. PubMed ID: 37951806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
    Ohno E; Hirooka Y; Itoh A; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Goto H
    Ann Surg; 2009 Apr; 249(4):628-34. PubMed ID: 19300203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of Preoperative Imaging for Differentiation of Branch Duct Versus Mixed Duct Intraductal Papillary Mucinous Neoplasms.
    Ugbarugba EE; Grieco C; Hart PA; Li F; Sklaw B; Cronley K; Oza VM; Swanson BJ; Walker JP; El-Dika S; Conwell DL; Krishna SG
    Pancreas; 2018; 47(5):556-560. PubMed ID: 29683969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm.
    Hong HS; Yun M; Cho A; Choi JY; Kim MJ; Kim KW; Choi YJ; Lee JD
    Clin Nucl Med; 2010 Oct; 35(10):776-9. PubMed ID: 20838285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
    Baiocchi GL; Bertagna F; Gheza F; Grazioli L; Calanducci D; Giubbini R; Portolani N; Giulini SM
    Ann Surg Oncol; 2012 Oct; 19(11):3574-80. PubMed ID: 22752369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
    Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
    Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.
    Walter TC; Steffen IG; Stelter LH; Maurer MH; Bahra M; Faber W; Klein F; Bläker H; Hamm B; Denecke T; Grieser C
    Eur Radiol; 2015 May; 25(5):1329-38. PubMed ID: 25433414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
    Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.